It never ceases to amaze me who reads Pharma's Market. Like the Stanford University professor who wrote to set the record straight regarding my coverage from ASCO of the brain cancer vaccine from Pfizer and Avant.    Read More

First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.    Read More

Amylin fell more than 8% Monday after data from an important diabetes meeting sparked concern about competition to the drug Byetta. How to trade?   Read More

We are covering the ADA meeting today and tomorrow because most of the major data came out over the weekend or is coming out later today. Or so we thought.    Read More

The Dow tumbled badly Friday after oil shot up more than $11 to a new record. What's the "Word on the Street?"   Read More

"You continue--day after day--to knock the company at every opportunity. I understand you had a difficult relationship with the CEO before, but you shouldn't hold a grudge against the company for it..."   Read More

Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold.   Read More

Next week could be the biggest week for oil and other commodities in years, says Guy Adami. What's the "Word on the Street?"   Read More

Matt writes, “I bought Amylin today. What should I set as my target sell point?"   Read More

Following are the day’s biggest winners and losers. Find out why shares of Heinz and Big Lots popped while Marriott and gold dropped.   Read More